Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:03:51.642Z.
Calculation as of: 2026-10-06T17:03:51.642Z.
Quote observation: 2026-10-06T17:00:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 54b27289092361ea6502e61cba635145b9acb525321868e00b72fceafc9e89d3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$1.71B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.72B
EV/EBITDA Ratio
4.44x
TTM Avg
6.94x
3Y Avg
36.47x
5Y Avg
27.65x
Market Cap
$1.75B
EV/EBITDA Ratio
9.62x
TTM Avg
10.11x
3Y Avg
12.56x
5Y Avg
13.71x
Market Cap
$1.76B
EV/EBITDA Ratio
39.27x
TTM Avg
89.00x
3Y Avg
147.22x
5Y Avg
147.22x
Market Cap
$1.64B
EV/EBITDA Ratio
57.23x
TTM Avg
223.11x
3Y Avg
223.11x
5Y Avg
223.11x
Market Cap
$1.78B
EV/EBITDA Ratio
16.41x
TTM Avg
130.62x
3Y Avg
220.82x
5Y Avg
220.82x
Market Cap
$1.62B
EV/EBITDA Ratio
6.74x
TTM Avg
10.54x
3Y Avg
14.62x
5Y Avg
19.17x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Personalis, Inc. (PSNL) | $1.71B | N/A | N/A | N/A | N/A |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.71B | N/A | N/A | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.72B | 4.44x | 6.94x | 36.47x | 27.65x |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | 9.62x | 10.11x | 12.56x | 13.71x |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.76B | 39.27x | 89.00x | 147.22x | 147.22x |
| Septerna Inc (SEPN)vs › | $1.65B | N/A | N/A | N/A | N/A |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.64B | 57.23x | 223.11x | 223.11x | 223.11x |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.78B | 16.41x | 130.62x | 220.82x | 220.82x |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.62B | 6.74x | 10.54x | 14.62x | 19.17x |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.61B | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
